zurück

Dolutegravir / abacavir / lamivudine (new indication: HIV infection; ≥ 14 kg and < 12 years of age)

 

Subject:

  • Active Substance: Dolutegravir / abacavir / lamivudine
  • Name: Triumeq®
  • Therapeutic area: HIV infection
  • Pharmaceutical company: ViiV Healthcare GmbH

 

Time table:

  • Start: 01.03.2023
  • Final decision by G-BA: 17.08.2023

 

Final decision:

  1. Therapy-naïve children weighing ≥ 14 kg and aged < 6 years: No additional benefit proved

  2. Therapy-naïve children weighing ≥ 14 kg and aged 6 to < 12 years: No additional benefit proved

  3. Pre-treated children weighing ≥ 14 kg and aged < 12 years: No additional benefit proved